Zynerba Pharmaceuticals
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$34,820,072 over the previous period. Total operating expenses were $35,251,540.

Profit Margin

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE): Profit margin
2013 943.90K -636.79K -67.46%
2014 810.01K -5.66M -699.94%
2015 278.9K -12.55M -4500.3%
2016 7.25K -23.38M -322600.1%
2017 7.25K -32.01M -441549.02%
2018 86K -39.91M -46408.34%
2019 0 -31.43M
2020 0 -50.40M
2021 0 -37.60M
2022 0 -34.82M

ZYNE Income Statement (2013 – 2022)

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue
Revenue
000086K7.25K7.25K278.9K810.01K943.90K
Cost of revenue
0000000000
Gross profit
000086K7.25K7.25K278.9K810.01K943.90K
Operating exp.
Research and development
21.09M21.42M35.65M20.38M27.24M22.80M16.78M7.44M2.40M1.13M
Selling and marketing
0000000000
Total operating expenses
35.25M36.77M52.06M34.31M40.48M32.82M23.21M12.81M6.47M1.57M
Operating income
-35.25M-36.77M-52.06M-34.31M-40.39M-32.82M-23.20M-12.53M-5.66M-634.43K
Other income (expenses), net
215.73K-538.63K725.71K1.37M-474.66K810.70K-288.64K7.35K-1.84K-2.35K
Income before tax
-35.03M-37.30M-51.33M-32.94M-39.91M-32.01M-23.41M-12.52M-5.66M-636.79K
Income tax expense
-215.73K291.49K-932.74K-1.51M486.65K-27.54K-27.54K27.54K00
Net income
-34.82M-37.60M-50.40M-31.43M-39.91M-32.01M-23.38M-12.55M-5.66M-636.79K
Earnings per share
Basic EPS
-0.82-0.96-1.87-1.43-2.61-2.48-2.58-2.82-0.99-0.11
Diluted EPS
-0.82-0.96-1.87-1.43-2.61-2.48-2.58-2.82-0.99-0.11
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData source